Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price traded down 1.6% during trading on Thursday . The stock traded as low as C$8.01 and last traded at C$8.01. Approximately 1,419 shares changed hands during mid-day trading, an increase of 17% from the average session volume of 1,212 shares. The stock had previously closed at C$8.14.
Devonian Health Group Stock Down 6.4%
The firm has a market cap of C$20.86 million, a PE ratio of -2.16 and a beta of 0.44. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36. The business has a 50-day moving average price of C$10.60 and a two-hundred day moving average price of C$11.37.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Read More
- Five stocks we like better than Devonian Health Group
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
- MarketBeat Week in Review – 06/29 – 07/03
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
